Kim J K, Tsen M F, Ghetie V, Ward E S
Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas 75235-8576.
Eur J Immunol. 1994 Oct;24(10):2429-34. doi: 10.1002/eji.1830241025.
Site-directed mutagenesis of a recombinant Fc hinge fragment has recently been used to localize the site of the murine IgG1 molecule that is involved in the control of catabolism (the "catabolic site"). In the current study, the effects of these CH2 and CH3 domain mutations (Ile 253 to Ala 253, His 310 to Ala 310, Gln 311 to Asn 311, His 433 to Ala 433 and Asn 434 to Gln 434) on intestinal transfer of Fc hinge fragments in neonatal mice have been analyzed. Studies using direct transfer and competition assays demonstrate that the mutations affect the transmission from intestinal lumen into serum in a way that correlates closely with the effects of the mutations on pharmacokinetics. Binding studies of several of the Fc hinge fragments to isolated neonatal brush borders have been used to confirm the in vivo transmission data. These analyses have resulted in the localization of the binding site for the intestinal transfer receptor, FcRn, to specific residues of the murine Fc hinge fragment. These residues are located at the CH2-CH3 domain interface and overlap with both the catabolic site and staphylococcal protein A (SpA) binding site. The pH dependence of IgG1 or Fc fragment binding to FcRn is consistent with the localization of the FcRn interaction site to a region of the Fc that encompasses two histidine residues (His 310 and His 433). To assess whether one or two FcRn binding sites per Fc hinge are required for intestinal transfer, a hybrid Fc hinge fragment comprising a heterodimer of one Fc hinge with the wild-type IgG1 sequence and a mutant Fc hinge with a defective catabolic site (mutated at His 310, Gln 311, His 433 and Asn 434) has been analyzed in direct and competition transmission assays. The studies demonstrate that the Fc hybrid is transferred with significantly reduced efficiency compared to the wild type Fc hinge homodimer and indicate that the binding to FcRn, and possibly subsequent transfer, is enhanced by the presence of two FcRn binding sites per Fc hinge fragment.
重组Fc铰链片段的定点诱变最近已被用于定位参与分解代谢控制的鼠IgG1分子的位点(“分解代谢位点”)。在当前研究中,分析了这些CH2和CH3结构域突变(Ile 253突变为Ala 253、His 310突变为Ala 310、Gln 311突变为Asn 311、His 433突变为Ala 433以及Asn 434突变为Gln 434)对新生小鼠Fc铰链片段肠道转运的影响。使用直接转运和竞争试验的研究表明,这些突变影响从肠腔到血清的转运,其方式与突变对药代动力学的影响密切相关。对几种Fc铰链片段与分离的新生小鼠刷状缘的结合研究已用于证实体内转运数据。这些分析已将肠道转运受体FcRn的结合位点定位到鼠Fc铰链片段的特定残基。这些残基位于CH2-CH3结构域界面,与分解代谢位点和葡萄球菌蛋白A(SpA)结合位点重叠。IgG1或Fc片段与FcRn结合的pH依赖性与FcRn相互作用位点定位到包含两个组氨酸残基(His 310和His 433)的Fc区域一致。为了评估每个Fc铰链是否需要一个或两个FcRn结合位点进行肠道转运,在直接和竞争转运试验中分析了一种杂合Fc铰链片段,该片段由一个具有野生型IgG1序列的Fc铰链和一个具有缺陷分解代谢位点(在His 310、Gln 311、His 433和Asn 434处突变)的突变Fc铰链的异二聚体组成。研究表明,与野生型Fc铰链同二聚体相比,Fc杂合体的转运效率显著降低,表明每个Fc铰链片段存在两个FcRn结合位点可增强与FcRn的结合以及可能随后的转运。